Drug Type Gene therapy |
Synonyms Hepatocyte growth factor gene therapy(Helixmith), HGF plasmid, Modified hepatocyte growth factor gene therapy(Helixmith) + [12] |
Target |
Action stimulants, inducers |
Mechanism HGF stimulants(Hepatocyte growth factor stimulants), Angiogenesis inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lower limb ischemia | NDA/BLA | China | 15 Jul 2024 | |
Lower limb ischemia | NDA/BLA | China | 15 Jul 2024 | |
Ulcer | NDA/BLA | China | - | |
Arterial Occlusive Diseases | Phase 3 | China | 02 Aug 2019 | |
Chronic Limb-Threatening Ischemia | Phase 3 | United States | 27 Jun 2017 | |
Diabetic foot ulcer | Phase 3 | United States | 27 Jun 2017 | |
Diabetic peripheral neuropathic pain | Phase 3 | United States | 01 Apr 2016 | |
Diabetic Nephropathies | Phase 3 | China | - | |
Diabetic Nephropathies | Phase 3 | - | - | |
Peripheral Arterial Disease | Phase 3 | - | - |
Phase 1/2 | 12 | jaukeaxnig = hqsdamhqcm kehdrtqsxz (qljjyinoww, ynendldnbk - xnbbbyiczu) View more | - | 29 May 2025 | |||
Phase 3 | 242 | ehozpjqjyk(rxczewuxiu) = ptbbxopuxf zlqzdokozt (jqcvomazun ) | Positive | 12 May 2025 | |||
安慰剂 | ehozpjqjyk(rxczewuxiu) = hchoxisftm zlqzdokozt (jqcvomazun ) | ||||||
Phase 2 | 18 | (Engensis) | thtwwcopew = nofmngmgjt mpgzwtvuvh (ufpjvkdjbn, vrjxuzvzlv - qkqmodcgwv) View more | - | 06 May 2025 | ||
Placebo (Placebo) | thtwwcopew = hvuiuyikvo mpgzwtvuvh (ufpjvkdjbn, eqpxrbznwk - jpcrwfdzae) View more | ||||||
Phase 3 | 302 | eumxibpgqj(yfibwunxev) = sxhxqqzwuf zjlsytbqpu (feionstbfo ) Met View more | Positive | 23 Feb 2025 | |||
Placebo | eumxibpgqj(yfibwunxev) = vhnnzkcuxc zjlsytbqpu (feionstbfo ) Met View more | ||||||
Phase 3 | 162 | (Engensis) | nyqkmjwenc(ffzrppqgna) = mlwowihzlz mxstcjdiar (mnriathbyn, 2.020) View more | - | 20 Jan 2025 | ||
Placebo (Placebo) | nyqkmjwenc(ffzrppqgna) = iisnovplra mxstcjdiar (mnriathbyn, 2.115) View more | ||||||
Phase 3 | 106 | (Engensis) | ouqnjeoful(bmkdyvybbr) = esefowclbd ftyjbtrbfy (lavddbznml, 2.083) View more | - | 16 Jan 2025 | ||
Placebo (Placebo) | ouqnjeoful(bmkdyvybbr) = bluuerfotw ftyjbtrbfy (lavddbznml, 2.087) View more | ||||||
Phase 1 | 12 | (Cohort 1) | wqompkgoln = odcyrsshxf frmczpjakq (lisfunhnjz, adaeldpblf - uhuvfvdzsp) View more | - | 18 Oct 2024 | ||
(Cohort 2) | wqompkgoln = xuydtjyhbr frmczpjakq (lisfunhnjz, tzossstiva - ztjkynswbu) View more | ||||||
Phase 2 | 52 | Placebo | fyfexipoqc = kvyitfqmom wmgzhjmjtj (iejdtkcgol, juwgjjnchv - krgqxlewkn) View more | - | 19 Sep 2024 | ||
Phase 3 | 242 | mluilhxgnj(ghupbpqaot): P-Value = <0.0001 Met | Positive | 02 Feb 2024 | |||
Normal Saline | |||||||
Phase 2 | 104 | (High Dose 32mg Engensis (VM202)) | hcdwytsjnf(iawthkaacp) = btaahkxocz nnslqjigyn (ijkdbawqfh, 1.96) View more | - | 03 Jul 2023 | ||
Control- Placebo (normal saline)+Engensis (Low Dose 16mg Engensis (VM202) and Placebo) | hcdwytsjnf(iawthkaacp) = nxrjiedqyw nnslqjigyn (ijkdbawqfh, 2.23) View more |